Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country symbols : Urgn save search
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
association for meeting benefits
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.64%
H: 0.71%
C: -2.43%
pharma patent pharmaceuticals teva
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
Published: 2024-03-04 (Crawled : 13:30) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 0.73%
H: 4.08%
C: 2.91%
pharma report financial results
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.23%
H: 5.34%
C: 5.34%
pharma conference health care
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
Published: 2024-01-24 (Crawled : 14:30) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 4.24%
H: 0.0%
C: -4.51%
ugn-102 fda submission
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
Published: 2023-07-10 (Crawled : 14:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.77%
H: 2.83%
C: -4.55%
jelmyto kidney tumors study
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
Published: 2023-07-06 (Crawled : 14:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 0.0%
H: 5.12%
C: 5.08%
ugn-102 pharma
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
Published: 2023-06-20 (Crawled : 23:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: -4.96%
jelmyto study
UroGen Pharma to Present at Upcoming Investor Conferences - June 2, 2023
Published: 2023-06-02 (Crawled : 12:20) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 0.92%
H: 1.32%
C: -1.22%
pharma
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
Published: 2023-05-04 (Crawled : 13:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.08%
H: 1.25%
C: -2.19%
pharma report financial results
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
Published: 2023-04-25 (Crawled : 12:20) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.43%
H: 6.61%
C: 0.96%
pharma conference
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
Published: 2023-03-16 (Crawled : 13:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 1.66%
H: 0.1%
C: -4.7%
pharma year growth
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
Published: 2023-02-15 (Crawled : 16:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.75%
H: 3.01%
C: -1.29%
ugn-102 treatment home bladder therapy cancer
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Published: 2022-11-10 (Crawled : 14:20) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -1.46%
H: 0.58%
C: -15.08%
pharma financial results
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
Published: 2022-10-11 (Crawled : 12:20) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.32%
ugn-102 pharma bladder cancer
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
Published: 2022-05-13 (Crawled : 13:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 3.96%
H: 1.43%
C: -5.56%
pharma
UroGen Pharma to Present at Upcoming Conferences
Published: 2022-01-05 (Crawled : 14:00) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.55%
H: 2.44%
C: 0.22%
conference pharma
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
Published: 2021-12-21 (Crawled : 14:30) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: 0.42%
H: 1.84%
C: -4.0%
ugn-102 risk bladder cancer media cancer bladder
UroGen Pharma Announced Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2021-12-03 (Crawled : 13:30) - biospace.com/
URGN | $14.53 1.11% 0.96% 220K
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
granted grant pharma
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
PEB 4 | $15.45 2.45% 10.46% 130
|
Finance
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
Your saved searches
Save your searches and get alerts when important news are released.